Shares of Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) rose 98,180% during trading on Thursday . The company traded as high as $0.15 and last traded at $147.42. Approximately 100 shares changed hands during trading, a decline of 86% from the average daily volume of 720 shares. The stock had previously closed at $0.15.
Orgenesis Price Performance
The company’s 50-day moving average price is $0.33 and its two-hundred day moving average price is $0.50. The company has a market capitalization of $743,845.00, a price-to-earnings ratio of -0.02 and a beta of 3.44.
About Orgenesis
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Recommended Stories
- Five stocks we like better than Orgenesis
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
